Immunic (NASDAQ:IMUX) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Immunic (NASDAQ:IMUX) from a sell rating to a hold rating in a research note published on Friday.

A number of other analysts have also recently weighed in on IMUX. Brookline Capital Management reiterated a buy rating and set a $10.00 price target on shares of Immunic in a research report on Friday, April 5th. Piper Sandler reiterated an overweight rating and set a $28.00 price target on shares of Immunic in a research report on Tuesday, July 16th.

Immunic Stock Down 3.1 %

Shares of NASDAQ IMUX opened at $1.25 on Friday. The stock’s 50 day moving average price is $1.25 and its two-hundred day moving average price is $1.27. The stock has a market capitalization of $112.60 million, a P/E ratio of -0.68 and a beta of 1.76. Immunic has a 52-week low of $0.95 and a 52-week high of $2.01.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. On average, analysts anticipate that Immunic will post -0.94 EPS for the current year.

Institutional Trading of Immunic

Several large investors have recently added to or reduced their stakes in IMUX. Virtu Financial LLC acquired a new stake in Immunic in the 1st quarter valued at approximately $25,000. Summit Trail Advisors LLC bought a new position in Immunic during the 1st quarter valued at $25,000. Sierra Summit Advisors LLC bought a new position in Immunic during the 4th quarter valued at $487,000. Ikarian Capital LLC boosted its stake in Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after purchasing an additional 1,162,378 shares in the last quarter. Finally, Gratus Capital LLC boosted its stake in Immunic by 15.1% during the 4th quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock valued at $2,912,000 after purchasing an additional 254,999 shares in the last quarter. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.